Výsledky vyhledávání - "Melanie, Chan"

Diverse ancestry whole-genome sequencing association study identifies TBX5 and PTK7 as susceptibility genes for posterior urethral valves

Autor: Catalin Voinescu, Daniel Gale, Melanie Chan

Publikováno v: eLife. 11

Posterior urethral valves (PUV) are the commonest cause of end-stage renal disease in children, but the genetic architecture of this rare disorder remains unknown. We performed a sequencing-based genome-wide association study (seqGWAS) in 132 unrelat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05e3ae5d28c473fce62e83635eae2025
https://doi.org/10.7554/elife.74777

Zobrazit plný text záznamu

Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA

Publikováno v: J Am Soc Nephrol
Journal of the American Society of Nephrology, 33(2), 305-325. AMER SOC NEPHROLOGY
Journal of the American Society of Nephrology, 33, 305-325
Journal of the American Society of Nephrology, 33, 2, pp. 305-325

Contains fulltext : 248375.pdf (Publisher’s version ) (Closed access) BACKGROUND: Gitelman syndrome is the most frequent hereditary salt-losing tubulopathy characterized by hypokalemic alkalosis and hypomagnesemia. Gitelman syndrome is caused by bi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a337d9b6caae0450c90e5de3c4feae
https://europepmc.org/articles/PMC8819995/

Zobrazit plný text záznamu

Elektronická kniha

Digital Reality : The Body and Digital Technologies

Autor: Melanie Chan

As contemporary scholars, journalists, and commentators have indicated, mobile digital devices promote a constant shift of attention between the world around us and the stimulations afforded by screen-based interfaces. Investigating these uniquely co

Zobrazit plný text záznamu

Akademický článek

Outcomes of Chronic Hemodialysis Patients in the Intensive Care Unit

Autor: Melanie Chan, Marlies Ostermann

Publikováno v: Critical Care Research and Practice, Vol 2013 (2013)

Patients with end-stage renal disease (ESRD) experience higher rates of hospitalisation, cardiovascular events, and all-cause mortality and are more likely to require admission to the intensive care unit (ICU) than patients with normal renal function

Externí odkaz: https://doaj.org/article/51a6c1ca419b465e982c20cd1655e969

Zobrazit plný text záznamu

SAT0089 SAFETY AND EFFICACY OF LY3337641, A BRUTON’S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY

Autor: Lai Shan (Melanie) Chan, Jeannie Chao, Anna Dudek, Ajay Nirula, Akira Sagawa, Alan Kivitz, William Barchuk, Mark C. Genovese, Alberto Spindler, Won Park

Publikováno v: SATURDAY, 15 JUNE 2019.

Background LY3337641 is an irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK), a key signaling molecule in the B-cell-receptor and Fc-receptor pathways and mediator of B-cell– and myeloid-cell–dependent inflammatory arthritis.1,2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::748526a183f4c6ef17b38fdbb5af2543
https://doi.org/10.1136/annrheumdis-2019-eular.2672

Zobrazit plný text záznamu

Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study

Autor: Jeannie Chao, Ajay Nirula, Lai Shan Melanie Chan, Won Park, William Barchuk, Alan Kivitz, Jennifer Witcher, Anna Dudek, Alberto Spindler, Akira Sagawa, Mark C. Genovese

Publikováno v: The Journal of rheumatology. 48(7)

Objective.To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton’s tyrosine kinase in a 2-part, phase II trial (RAjuvenate; ClinicalTrials.gov: NCT02628028) in adults with active

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b526556b318f83fe4a47b58abcd89e60
https://pubmed.ncbi.nlm.nih.gov/33858981

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání